The Google Calico business to delay death was announced on or about Sept. 18, 2013. Larry Page himself made the announcement on Google Plus. Although the new Calico business may or may not involve gadgets Mr. Page and Google are both local (Mr. Page is from East Lansing). Not local to this area is Arthur D. Levinson (CEO of Genentech, Chairman of Apple) will be the "chairman of Calico and the founding investor". A more appropriate descriptor for the new business might be "life expectancy management".
Those who have suffered through a loved one's prolonged and sometimes painful passage will have some sympathy with this venture. However, Calico is so new that a physical business address is yet to be located. The closest one found is that of the "ghost town" Calico. Is that an intended irony? TIME argues for the cat mythos of having "nine lives". And what could the valuation be for such a business investment? ABC News says the Google $ to be put in the venture isn't being reported. ABC went on to post that by close of business Sept. 18, 2013 Google stock rose 2%.
Plus, Google Health got yanked some time ago - so results for Calico are a must. A quick review of Google's Form 10-K 2012 filing with the SEC does not appear to show any leanings to this type of venture. But a general review of their numbers shows that a 2% rise in value one day is fairly "awesome". So how much in "research dollars" will be committed to the new Calico life expectancy management venture? Their research dollars seemed to rise about "0.8%" per year. One might expect that much investment (or even double?) in the Calico business.
What about the business side of Genentech? Net income and profits were reportedly growing up to 2007 (with a huge increase in the company's valuation). Also of interest (to the Calico business venture) are their stable of cancer products. Controversy in the business is not unknown - but it must be good to be so close to the U. S. Congress? And it won't hurt to have a Calico/Google/Genentech booth at the trade shows. But this new form of data-crunching health business to fight off major causes of biological death might just be good for business - and the suffering millions around us.